✦ LIBER ✦

Transitional cell carcinoma of bladder in pediatric patients

✍ Scribed by Sandra BATTAGLIA Francesca DIOMEDI CAMASSEI∗; Nicola CAPOZZA; Paolo CAIONE

Book ID: 118479670
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 43 KB
Volume: 3
Category: Article
ISSN: 1477-5131
DOI: 10.1016/j.jpurol.2007.01.065

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-grade transitional cell carcinoma o

High-grade transitional cell carcinoma of the pediatric bladder

✍ Garrett S. Korrect; Eugene A. Minevich; Bezalel Sivan 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 572 KB

Cellular fibronectin in patients with tr

Cellular fibronectin in patients with transitional cell carcinoma of the bladder

✍ Axel Hegele; Axel Heidenreich; Zoltan Varga; Rolf von Knobloch; Peter Olbert; Jü 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 180 KB

Recurrence risk factors in patients with

Recurrence risk factors in patients with transitional cell carcinoma of bladder

✍ Xiang-hui Yue; Xiao-hong Yang; Fu-qing Zheng 📂 Article 📅 2005 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 409 KB

Transitional cell carcinoma of bladder i

Transitional cell carcinoma of bladder in patients under thirty years of age

✍ John P. McCarthy; George J. Gavrell; Gilbert A. Leblanc 📂 Article 📅 1979 🏛 Elsevier Science 🌐 English ⚖ 313 KB

Immunological Profile of Patients with T

Immunological Profile of Patients with Transitional Cell Carcinoma of the Bladder

✍ E. MUKAMEL; B. SHOHAT; C. SERVADIO 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Adjuvant Bestatin immunotherapy in patie

Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder

✍ Henric Blomgren; Ingemar Näslund; Pier-Luigi Esposti; Lise Johansen; Ove Aaskove 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 554 KB

The first clinical results of an ongoing, prospective trial to determine the value of adjuvant Bestatin immunotherapy in the management of bladder cancer are presented. Patients with nonmetastatic transitional cell carcinoma of the bladder, scheduled for full dose local radiation therapy (64 Gy), we